A phase I/IIa clinical trial of JAB-24114 in the China
Latest Information Update: 01 Sep 2023
At a glance
- Drugs JAB 24114 (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
Most Recent Events
- 31 Aug 2023 New trial record